When synthetic cannabinoid compounds became controlled by state and federal governments, different, noncontrolled compounds began to appear as marijuana substitutes. Unlike the scheduled cannabinoids, the newer compounds have not been characterized for potency and efficacy in preclinical studies. The purpose of these experiments was to determine whether some of the more recent synthetic compounds sold as marijuana substitutes have behavioral effects similar to those of Δ 9 -tetrahydrocannabinol (Δ 9 -THC), the pharmacologically active compound in marijuana. The compounds UR-144, XLR-11, AKB-48 (APINACA), PB-22 (QUPIC), 5F-PB-22, and AB-FUBINACA were tested for locomotor depressant effects in male Swiss-Webster mice and subsequently for their ability to substitute for Δ 9 -THC (3 mg/kg, intraperitoneally) in drug discrimination experiments with male Sprague-Dawley rats. UR-144, XLR-11, AKB-48, and AB-FUBINACA each decreased locomotor activity for up to 90 min, whereas PB-22 and 5F-PB-22 produced depressant effects lasting 120-150 min. Each of the compounds fully substituted for the discriminative stimulus effects of Δ 9 -THC. These findings confirm the suggestion that these compounds have marijuana-like psychoactive effects and abuse liability. Behavioural Pharmacology 26:460-468 Copyright
Introduction
Recreational use of synthetic cannabinoids has been increasing despite efforts to control the availability of these compounds (Drug Enforcement Administration, 2014b) . New, unregulated compounds appear once older compounds become controlled under state and national laws. Most of these compounds have been described in the scientific literature or patented as potential lead compounds; however, others, for example, APINACA (AKB-48, N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide), seem to have been synthesized expressly for recreational drug trade and have not appeared in the scientific literature. On the basis of the rapid appearance of new compounds, the Drug Enforcement Agency (DEA) has been requesting temporary scheduling of recreationally used compounds when they are discovered instead of waiting for scientific analysis. UR-144 [(1-pentylindol-3-yl) (2,2,3,3-tetramethylcyclopropyl)methanone], XLR-11 [5F-UR-144, [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone], and AKB-48 were temporarily scheduled on 16 May 2013 (Drug Enforcement Administration, 2013) , and PB-22 (QUPIC, quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate), 5F-PB-22 [quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate], and AB-FUBINACA [N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide] were temporarily scheduled on 10 January 2014 (Drug Enforcement Administration, 2014a).
These compounds were identified as high risk by the DEA, and independent investigators have confirmed their sale and use. Four of the six compounds (UR-144, XLR-11, AKB-48, and AB-FUBINACA) have been identified in samples of synthetic cannabinoids obtained on the street (Kavanagh et al., 2013; Uchiyama et al., 2013; Strano Rossi et al., 2014) . All six of the compounds have been found in blood or urine samples (or identified by verbal report) of users reporting adverse effects (Behonick et al., 2014; Gugelmann et al., 2014; Mohr et al., 2014; Strano Rossi et al., 2014) , and the use of UR-144 or XLR-11 has been reported in cases of driving under the influence (Lemos, 2014; Musshoff et al., 2014) . Of further concern, several of these compounds have been reported to produce significant adverse effects. For example, PB-22 causes convulsions in humans and canines (Gugelmann et al., 2014) and 5F-PB-22 was found to be involved in three cases of sudden death (Behonick et al., 2014) . Renal toxicity associated with the use of synthetic cannabinoids has also been reported, with XLR-11 being identified in several of the cases (Centers for Disease Control and Prevention, 2013; Buser et al., 2014) .
It has been previously observed that synthetic cannabinoids are not merely other forms of Δ 9 -tetrahydrocannabinol (Δ 9 -THC; Fantegrossi et al., 2013) . These compounds have chemical structures unrelated to Δ 9 -THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014) . As shown in Fig. 1 , UR-144, XLR-11, PB-22, and 5F-PB-22 have central indole rings, whereas AKB-48 and AB-FUBINACA have indazole rings. Although pharmacological information on these compounds is scant, it has been reported that UR-144 binds to both cannabinoid 1 (CB1) and CB2 receptors (Frost et al., 2010) and that UR-144 and XLR-11 depress locomotor activity and fully substitute for the discriminative stimulus effects of Δ 9 -THC (Wiley et al., 2013) .
The purpose of the present study was to determine whether the six cannabinoids listed above are psychoactive and may produce subjective effects similar to that of Δ 9 -THC. The mouse locomotor activity test was used to measure depressant effects common to cannabinoids. Drug discrimination procedures, which have a long history of being a useful animal model of the subjective effects of drugs that may predict abuse liability (Balster, 1991; Horton et al., 2013) , were used in rats to test for the ability of the six cannabinoid compounds to produce discriminative stimulus effects similar to those of Δ 9 -THC.
Methods

Subjects
Male ND4 Swiss-Webster mice were obtained from Harlan Laboratories (Indianapolis, Indiana, USA) at ∼ 8 weeks of age and maintained at the University of North Texas Health Science Center animal facility for 2 weeks before testing. Mice were housed three to four per cage on a 12 : 12-h light/dark cycle (lights on at 07:00 h) and were allowed free access to food and water except during test sessions. Male Sprague-Dawley rats were obtained from Harlan Laboratories. All rats were housed individually and were maintained on a 12 : 12 light/dark cycle (lights on at 07:00 h). Body weights were maintained at 320-350 g by limiting food to 15 g/day, which included the food received during operant sessions. Water was continuously available in the home cage. All housing and procedures were in accordance with the -THC (1-30 mg/kg), UR-144 (1-30 mg/kg), XLR-11 (1-30 mg/kg), AKB-48 (1-30 mg/kg), PB-22 (0.05-0.5 mg/kg), 5F-PB-22 (0.1-1.0 mg/kg), or AB-FUBINACA (0.5-5 mg/kg), immediately before locomotor activity testing. Only seven mice were tested following the 1 mg/kg dose of UR-144. Each dose range included doses that were without effect to those that produced at least 50% depression below vehicle control. In all studies, horizontal activity (interruption of photocell beams) was measured for 8 h within 10-min periods, beginning at 08:00 h (1 h after lights on). Behavioral observations of each mouse were recorded at 30, 120, and 480 min after the highest dose tested.
Discrimination procedures
Standard
behavior-testing chambers (Coulbourn Instruments, Allentown, Pennsylvania, USA) were connected to IBM-PC compatible computers through Med Associates interfaces (East Fairfield, Vermont, USA). The computers were programmed in Med-PC for Windows, version IV (Med Associates) for the operation of the chambers and collection of data.
A pool of rats were first trained to discriminate Δ 9 -THC (3 mg/kg) from vehicle (ethanol/Cremophor EL/0.9% saline 1 : 1 : 18) using a two-lever choice methodology. Thirty minutes before the training sessions, the rats received an injection of either saline or Δ 9 -THC and were subsequently placed in the behavior-testing chambers, where food (45 mg food pellets; Bio-Serve, Frenchtown, New Jersey, USA) was available as a reinforcer for every 10 responses on a designated injection-appropriate lever. Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. Rats were used in tests of substitution of the experimental compounds once they had achieved nine of 10 sessions at 85% or greater injection-appropriate responding for both the first reinforcer and the total session, which occurred after ∼ 60 training sessions. The training sessions were conducted on separate days in a doublealternating manner (drug-drug-vehicle-vehicle-drug, etc.) until the training phase was complete, after which substitution tests were introduced into the training schedule, such that at least one vehicle and one drug session occurred between each test (drug-vehicle-test--vehicle-drug-test-drug, etc.) . The substitution tests were conducted only if the rats had achieved 85% injection-appropriate responding on the two prior training sessions.
During the test sessions, both the levers were active, such that 10 consecutive responses on either lever led to reinforcement. For dose-effect experiments, data were collected until the first reinforcer was obtained, or for a maximum of 20 min. Each compound was tested in a separate group of six rats using a repeated-measures design, such that each rat was tested at all doses of a given drug. Vehicle and Δ 9 -THC (3 mg/kg) controls were tested before the start of each compound evaluation. Intraperitoneal injections (1 ml/kg) of vehicle, UR-144 (0.1-5 mg/kg), AKB-48 (0.025-2.5 mg/kg), and 5F-PB-22 (0.01-0.5 mg/kg) were administered 30 min before the start of the test session. XLR-11 (0.05-1 mg/kg), PB-22 (0.1-0.5 mg/kg), and AB-FUBINACA (0.05-1 mg/kg) were administered 15 min before the start of the test session. A dose range was tested from no effect (< 20% Δ 9 -THC-appropriate responding) to full effect (≥80% Δ 9 -THC-appropriate responding or suppression of responding to < 20% of vehicle control). Pretreatment times were based on the time of peak depression for each compound in locomotor activity testing.
For the time-course experiments, a repeated-measures design was used, such that each rat was tested at several time points following a single administration of the test compound. The lowest dose that fully substituted without significant rate effects in the dose-effect studies was selected. The rats were injected with the test compound and placed in the test chambers 5 min after administration. Data were collected until the first reinforcer was obtained or for a maximum of 5 min, and the rats were immediately removed from the chambers. Testing was repeated at 15, 30, 60, and 120 min after administration. If necessary, testing was continued at 4, 8, 24, and 48 h after administration until Δ 9 -THC-appropriate responding had decreased to below 30-40%.
, and AB-FUBINACA [N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide] were provided by the National Institute on Drug Abuse Drug Supply Program. All drugs were dissolved in ethanol/Cremophor EL/0.9% saline (1 : 1 : 18) and were administered intraperitoneally in a volume of 1 ml/kg.
Data analysis
Locomotor activity data were expressed as the mean number of photocell counts in the horizontal plane (ambulation counts) during each 10-min period of testing. A 30-min period, beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data and calculation of ED50 values. OriginGraph (OriginLab Corporation, Northampton, Massachusetts, USA) was used to estimate the maximal depression induced by each cannabinoid. The ED50 values were calculated by estimating the dose producing half of maximal depression (0 photocell counts) from the descending linear portion of the dose-response curve. A two-way analysis of variance, with dose as a between-groups factor and time as a within-subjects factor, was carried out on horizontal activity counts/10-min interval. Subsequently, a one-way analysis of variance was carried out on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-offreedom F-tests.
Drug discrimination data are expressed as the mean percentage of drug-appropriate responses occurring during each test period. Rates of responding were expressed as a function of the number of responses made divided by the time to the first reinforcer. Graphs for percent drugappropriate responding and response rate were plotted as a function of dose of test compound (log scale). Percent drug-appropriate responding was shown only if at least three rats completed the first fixed ratio, whereas all rats are shown for the response rate data. Full substitution was defined as at least 80% drug-appropriate responding and no statistical difference compared with the training drug. The potencies of UR-144, XLR-11, AKB-48, PB-22, 5F-PB-22, and AB-FUBINACA were calculated by fitting straight lines to the dose-response data for each compound using OriginGraph (OriginLab Corporation). Straight lines were fitted to the linear portion of dose-effect curves, including not more than one dose producing less than 20% of the maximal effect and not more than one dose producing more than 80% of the maximal effect. Other doses were excluded from the analyses. Response rate data were analyzed by one-way repeated-measures analysis of variance. Effects of individual doses were compared with the vehicle control value using a-priori contrasts. The criterion for significance was set a priori at P less than 0.05.
Results
Locomotor activity 
Drug discrimination
All of the test compounds (UR-144, XLR-11, AKB-48, PB-22, 5F-PB-22, and AB-FUBINACA) fully substituted for the discriminative stimulus effects of 3 mg/kg Δ 9 -THC (Fig. 3) . The ED50 values for each compound are shown in Table 1 . UR-144, XLR-11, and 5F-PB-22 produced no effects on response rate. AKB-48 did not produce statistically significant decreases in the response rate, but responding was suppressed in one of six rats at the dose that fully substituted (2.5 mg/kg). PB-22 decreased the response rate [F(3,15) = 5.20, P < 0.02] and two of six rats failed to respond at the dose that fully substituted (0.5 mg/kg). AB-FUBINACA also suppressed response rate [F(5,25) = 2.88, P < 0.05], and two of six rats failed to respond at the dose that fully substituted (1 mg/kg).
The results of the time-course studies are shown in Fig. 4 . UR-144 (2.5 mg/kg) fully substituted for the discriminative stimulus effects of 3 mg/kg Δ 9 -THC at 15 and 60 min after administration, and drug-appropriate responding was diminished to less than 40% after 4 h. No effect of UR-144 on the response rate was observed. XLR-11 (1 mg/kg) fully substituted from 5 to 15 min after administration, and drug-appropriate responding was nearly absent by 60 min. No effect on response rate was observed for this dose of XLR-11. AKB-48 (5 mg/kg) produced full substitution for the discriminative stimulus effects of Δ 9 -THC from 15 to 120 min after administration, and drug-appropriate responding had diminished to less than 50% at 4 h after administration. Response rate was increased at 15, 30, 60, and 120 min after administration of AKB-48 [F(6,30) = 4.85 P < 0.001].
PB-22 (0.5 mg/kg) fully substituted from 30 to 60 min after administration, and drug-appropriate responding decreased to vehicle levels after 8 h. Response rates were suppressed such that two of six rats failed to earn at least one reinforcer at 15 min, and three of six rats failed to earn at least one pellet at 30 min after administration. However, no statistically significant effect on response rate was observed, perhaps because response rates stayed the same or increased for the remaining rats, leading to increased variability. 5F-PB-22 (0.5 mg/kg) fully substituted for the discriminative stimulus effects of Δ 9 -THC from 30 to 60 min after administration. Drugappropriate responding was attenuated by 120 min after administration. Rates of responding were decreased at 5, 15, 30, and 60 min after 5F-PB-22 [F(5,25) = 3.87 THC-like effects of synthetic cannabinoids Gatch and Forster 465 P < 0.01], with marked suppression at 15 min after administration, such that four of six rats did not earn a food pellet. For AB-FUBINACA (0.5 mg/kg), substitution for Δ 9 -THC was present at 15 min and absent by 2 h after administration. Greater than 60% drug-appropriate responding persisted up to 1 h after administration. Depression of response rate was observed at 5 and 15 min after administration [F(5,25) = 2.68 P < 0.05].
Discussion
Six compounds temporarily assigned to schedule 1 by the DEA (UR-144, XLR-11, AKB-48, PB-22, 5F-PB-22, and AB-FUBINACA) were found to be active in rodent behavior assays. Each compound produced dosedependent depression of spontaneous locomotor activity similar to that produced by Δ 9 -THC. The synthetic cannabinoids were all at least as potent as Δ 9 -THC, and some were as much as 100-fold more potent than Δ 9 -THC. The rank order of potency for depression of locomotor activity was PB-22 = 5F-PB-22 > AB-FUBINACA = AKB-48 > UR-144 = XLR-11 = Δ 9 -THC. These findings confirm and extend previous findings that UR-144 and XLR-11 decrease locomotor activity in mice (Wiley et al., 2013) , as well as those of earlier studies indicating that a range of synthetic cannabinoids depress locomotor activity (Wiley et al., 1998; Gatch and Forster, 2014) .
All six of the test compounds also fully substituted for the discriminative stimulus effects of Δ 9 -THC in rats. These results confirm and extend previous findings that UR-144 and XLR-11 fully substitute for the discriminative stimulus effects of Δ 9 -THC in rats trained to discriminate Δ 9 -THC (Wiley et al., 2013) . Likewise, a number of other synthetic cannabinoids also fully substitute for the discriminative stimulus effects of Δ 9 -THC in mice (Brents et al., 2012) , rats (Järbe et al., 2011; Gatch and Forster, 2014; Wiley et al., 2014) , and monkeys (Ginsburg et al., 2012) . The test compounds appeared to be more potent at producing stimulus effects than Δ 9 -THC, but none of the calculated ED50 values differed significantly from that of Δ 9 -THC. Unlike Δ 9 -THC, some of the test compounds substituted only at doses that also decreased the rates of responding (PB-22, 5F-PB-22, and AB-FUBINACA). PB-22 produced full substitution at 0.5 mg/kg when tested in the dose-effect study using a 15 min pretreatment time. However, in the time-course study, only 73% drugappropriate responding was observed at 15 min. The variability between these results may be attributable to the rate-decreasing effects of PB-22. Only four of six rats responded after 0.5 mg/kg at 15 min after administration in both the time-course and the dose-effect studies. However, 100% THC-appropriate responding was observed at 30 and 60 min after 0.5 mg/kg PB-22, with little rate suppression at 60 min. AKB-48 (2.5 mg/kg) appeared to barely reach the 80% criterion for full substitution, and indeed less than 50% THC-appropriate responding was observed in a timecourse study of the 2.5 mg/kg dose (data not shown). However, 100% THC-appropriate responding was observed at 15-60 min after 5 mg/kg AKB-48, which indicates that AKB-48 can produce robust Δ 9 -THC discriminative stimulus effects depending on the parameters of the study. Similarly, UR-144 and AB-FUBINACA produced around 80% THC-appropriate responding in the time-course studies, but produced close to 100% THC-appropriate responding in the dose-effect studies. These differences between dose-effect and time-course studies are likely due to the variability in potency of these compounds across groups of animals. It is important to note that all of the test compounds produced substantial THC-like discriminative stimulus effects at a particular dose and time point, indicating their potential for abuse liability similar to that of cannabis.
Similar to a previous study of synthetic cannabinoids (Gatch and Forster, 2014) , the duration of the locomotor depressant effects of the test compounds did not predict the duration of their discriminative stimulus effects, neither did potency for the LMA depressant effects predict potency for substitution. For most of the test compounds, the ED50 values for drug discrimination were lower than those for locomotor activity: the differences ranged from three-fold to 60-fold. This difference in potency is in contrast to our work with psychostimulants, in which the locomotor stimulant effects of the test compounds in mice are highly predictive of the potency for the discriminative stimulus effects in rats, despite the physiological differences between the species (Gatch et al., 2013 (Gatch et al., , 2015 . The apparent disparity in the current studies may suggest that sedative or anxiolytic actions of cannabinoids are not salient components of their discriminative stimulus effects.
Before advancing to behavioral testing, all six of the test compounds were tested in assays developed and conducted by NovaScreen (PerkinElmer, Waltham, Massachusetts, USA) under contract with the National Institute on Drug Abuse Addiction Treatment Discovery Program, and the data were provided by the program. All of the compounds bind with nanomolar affinities to human recombinant CB1 receptors expressed in HEK-293 cells and act as full agonists -again, at nanomolar affinities -in CHO cells that express the human CB1 receptor (Table 2 ). It is noteworthy that functional activity at CB1 among the six test compounds was correlated with potency for Δ 9 -THC substitution (r 2 = 0.72, P = 0.02), but not locomotor depression (r 2 = 0.21, P = 0.20).
In summary, UR-144, XLR-11, AKB-48, PB-22, 5F-PB-22, and AB-FUBINACA produced locomotor depressant and discriminative stimulus effects similar to those produced by Δ 9 -THC. These findings, in combination with confirmation that they act as CB1 receptor agonists, suggest that these six compounds may have abuse liabilities similar to that of Δ 9 -THC, and to other illicit, controlled cannabinoids. Some of the test compounds produced substantial depressant effects on response rate, but no other adverse effects were observed at the doses and time points tested. Evidence that these compounds will produce reinforcing effects and maintain compulsive drug-seeking is necessary to establish that they have substantial abuse liability and need to be controlled to the same degree as Δ 9 -THC. 
